Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine

Anna P Durbin, Beth D. Kirkpatrick, Kristen K. Pierce, Alexander C. Schmidt, Stephen S. Whitehead

Research output: Contribution to journalArticle

Abstract

The Laboratory of Infectious Diseases at the National Institute of Allergy and Infectious Diseases, National Institutes of Health has been engaged in an effort to develop a safe, efficacious, and affordable live attenuated tetravalent dengue vaccine (LATV) for more than ten years. Numerous recombinant monovalent DENV vaccine candidates have been evaluated in the SCID-HuH-7 mouse and in rhesus macaques to identify those candidates with a suitable attenuation phenotype. In addition, the ability of these candidates to infect and disseminate in Aedes mosquitoes had also been determined. Those candidates that were suitably attenuated in SCID-HuH-7 mice, rhesus macaques, and mosquitoes were selected for further evaluation in humans. This review will describe the generation of multiple candidate vaccines directed against each DENV serotype, the preclinical and clinical evaluation of these candidates, and the process of selecting suitable candidates for inclusion in a LATV dengue vaccine.

Original languageEnglish (US)
Pages (from-to)7242-7250
Number of pages9
JournalVaccine
Volume29
Issue number42
DOIs
StatePublished - Sep 23 2011

Fingerprint

Dengue Vaccines
Vaccines
dengue
vaccines
Culicidae
Macaca mulatta
National Institute of Allergy and Infectious Diseases (U.S.)
Aedes
infectious diseases
National Institutes of Health (U.S.)
Communicable Diseases
National Institutes of Health
Phenotype
mice
hypersensitivity
serotypes
phenotype

Keywords

  • Clinical trial
  • Dengue
  • Vaccine development

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine. / Durbin, Anna P; Kirkpatrick, Beth D.; Pierce, Kristen K.; Schmidt, Alexander C.; Whitehead, Stephen S.

In: Vaccine, Vol. 29, No. 42, 23.09.2011, p. 7242-7250.

Research output: Contribution to journalArticle

Durbin, Anna P ; Kirkpatrick, Beth D. ; Pierce, Kristen K. ; Schmidt, Alexander C. ; Whitehead, Stephen S. / Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine. In: Vaccine. 2011 ; Vol. 29, No. 42. pp. 7242-7250.
@article{ca717dab6ddd4404b72c632df2f27101,
title = "Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine",
abstract = "The Laboratory of Infectious Diseases at the National Institute of Allergy and Infectious Diseases, National Institutes of Health has been engaged in an effort to develop a safe, efficacious, and affordable live attenuated tetravalent dengue vaccine (LATV) for more than ten years. Numerous recombinant monovalent DENV vaccine candidates have been evaluated in the SCID-HuH-7 mouse and in rhesus macaques to identify those candidates with a suitable attenuation phenotype. In addition, the ability of these candidates to infect and disseminate in Aedes mosquitoes had also been determined. Those candidates that were suitably attenuated in SCID-HuH-7 mice, rhesus macaques, and mosquitoes were selected for further evaluation in humans. This review will describe the generation of multiple candidate vaccines directed against each DENV serotype, the preclinical and clinical evaluation of these candidates, and the process of selecting suitable candidates for inclusion in a LATV dengue vaccine.",
keywords = "Clinical trial, Dengue, Vaccine development",
author = "Durbin, {Anna P} and Kirkpatrick, {Beth D.} and Pierce, {Kristen K.} and Schmidt, {Alexander C.} and Whitehead, {Stephen S.}",
year = "2011",
month = "9",
day = "23",
doi = "10.1016/j.vaccine.2011.07.023",
language = "English (US)",
volume = "29",
pages = "7242--7250",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "42",

}

TY - JOUR

T1 - Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine

AU - Durbin, Anna P

AU - Kirkpatrick, Beth D.

AU - Pierce, Kristen K.

AU - Schmidt, Alexander C.

AU - Whitehead, Stephen S.

PY - 2011/9/23

Y1 - 2011/9/23

N2 - The Laboratory of Infectious Diseases at the National Institute of Allergy and Infectious Diseases, National Institutes of Health has been engaged in an effort to develop a safe, efficacious, and affordable live attenuated tetravalent dengue vaccine (LATV) for more than ten years. Numerous recombinant monovalent DENV vaccine candidates have been evaluated in the SCID-HuH-7 mouse and in rhesus macaques to identify those candidates with a suitable attenuation phenotype. In addition, the ability of these candidates to infect and disseminate in Aedes mosquitoes had also been determined. Those candidates that were suitably attenuated in SCID-HuH-7 mice, rhesus macaques, and mosquitoes were selected for further evaluation in humans. This review will describe the generation of multiple candidate vaccines directed against each DENV serotype, the preclinical and clinical evaluation of these candidates, and the process of selecting suitable candidates for inclusion in a LATV dengue vaccine.

AB - The Laboratory of Infectious Diseases at the National Institute of Allergy and Infectious Diseases, National Institutes of Health has been engaged in an effort to develop a safe, efficacious, and affordable live attenuated tetravalent dengue vaccine (LATV) for more than ten years. Numerous recombinant monovalent DENV vaccine candidates have been evaluated in the SCID-HuH-7 mouse and in rhesus macaques to identify those candidates with a suitable attenuation phenotype. In addition, the ability of these candidates to infect and disseminate in Aedes mosquitoes had also been determined. Those candidates that were suitably attenuated in SCID-HuH-7 mice, rhesus macaques, and mosquitoes were selected for further evaluation in humans. This review will describe the generation of multiple candidate vaccines directed against each DENV serotype, the preclinical and clinical evaluation of these candidates, and the process of selecting suitable candidates for inclusion in a LATV dengue vaccine.

KW - Clinical trial

KW - Dengue

KW - Vaccine development

UR - http://www.scopus.com/inward/record.url?scp=80052406524&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052406524&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2011.07.023

DO - 10.1016/j.vaccine.2011.07.023

M3 - Article

VL - 29

SP - 7242

EP - 7250

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 42

ER -